Tuberculosis (TB) is a bacterial infection (Mycobacterium tuberculosis) that most often affects the lungs. Tuberculosis is transmitted from person to person through respiratory droplets.
Tuberculosis is a preventable and curable disease. But it is also the world’s deadliest infectious disease, killing more than AIDS and malaria combined.
Today, about ¼ of the world’s population has latent tuberculosis infection (LTBI), the stage when TB lies a dormant killer in the body without symptoms. Some persons are at greater risk of developing the disease: treating them successfully is key to changing the course of this epidemic.
What Sanofi does…
Since the 1950s, with the discovery of Rifamycins, still today the cornerstone of tuberculosis treatment, Sanofi has a sustained contribution in fighting tuberculosis and is committed to help reaching the objective to end TB epidemic by 203012.
As a health journey partner, Sanofi is strongly committed to stepping up the fight to eliminate tuberculosis. Including the treatment of latent tuberculosis infection in high risk populations.
We are developing a new global approach to contribute to eliminating tuberculosis:
• Global awareness campaign to expand the treatment coverage of latent tuberculosis infection
• New tools to improve educational efforts for healthcare professionals and general public
• Bolder partnerships and support to TB prevention and care to countries most in need
• Development of innovative and cost-effective therapeutic solutions, to answer unmet needs
Together we can eliminate tuberculosis once and for all!
11. WHO fact sheet Tuberculosis - https://www.who.int/news-room/fact-sheets/detail/tuberculosis - Accessed on February 9, 2021
12. United Sustainable Development Goals 3.3 - https://sustainabledevelopment.un.org/sdg3 - Accessed on March 24th 2020